US › Healthcare

Lakefront Biotherapeutics NV (LKFT)

US · Healthcare · Biotechnology

$26.45-1.08%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$6.5M

Revenue YoY

-91.4%

Net profit

$14.5M

Profit YoY

+109.4%

EPS

$0.21

EPS estimate

$-0.97

Net margin

223.6%

EPS came in at 0.21 against a street estimate of -0.97 — a beat of 121.6%.

Key statistics

Market cap

$1.75B

P/E

3.1

Forward P/E

344.8

P/B

0.48

Book value

$2.81

EPS (TTM)

$8.54

52-week high

$37.78

52-week low

$26.39

50-day MA

$28.74

200-day MA

$30.87

Beta

0.11

Analyst view

with an average price target of $25.48.

Shareholding

Insiders

25.35%

Institutions

22.60%

Largest institutional holders

Fund	Stake
TANG CAPITAL MANAGEMENT LLC	5.75%
Madison Avenue Partners, LP	3.74%
EcoR1 Capital, LLC	2.53%
Prosight Management, LP	2.35%
Ameriprise Financial Inc	2.16%
Segall Bryant & Hamill	0.65%
Point72 Asset Management, L.P.	0.50%
Renaissance Technologies Corp	0.48%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Lakefront Biotherapeutics NV — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.